WASHINGTON (Reuters) - After years of stagnant funding, medical research in the United States is set for a big cash infusion that experts expect will boost work on a range of ailments as well studies involving human embryonic stem cells.
WASHINGTON (Reuters) - After years of stagnant funding, medical research in the United States is set for a big cash infusion that experts expect will boost work on a range of ailments as well studies involving human embryonic stem cells.
